Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio- Engineered Sirolimus Eluting Stent) Post Market Registry

Trial Profile

Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio- Engineered Sirolimus Eluting Stent) Post Market Registry

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms REMEDEE-Registry
  • Most Recent Events

    • 02 Nov 2017 Results of pooled data from two trial (REMEDEE Registry and AIDA trial), were presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 02 Nov 2017 Final results of all-comers patients treated with COMBO stent with a follow-up of 3 years, were presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 23 Oct 2017 According to an OrbusNeich media release, data will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top